<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Steven M. Hyman</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Harvard University<br>Broad Institute</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0003-2605-0010" target="_blank">0000-0003-2605-0010</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Psychiatric disorders</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Genetics](/mechanisms/familial-alzheimers-genetics), Drug development</td>
</tr>
</table>
Steven M. Hyman
Overview
Steven M. Hyman is a leading researcher in the field of neurodegenerative diseases, affiliated with Harvard University and Broad Institute. Their research focuses on Genetics, Drug development, with particular emphasis on Alzheimer's Disease and Psychiatric disorders. With an h-index of 200, Hyman is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Steven M. Hyman</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Harvard University<br>Broad Institute</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0003-2605-0010" target="_blank">0000-0003-2605-0010</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Psychiatric disorders</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Genetics](/mechanisms/familial-alzheimers-genetics), Drug development</td>
</tr>
</table>
Steven M. Hyman
Overview
Steven M. Hyman is a leading researcher in the field of neurodegenerative diseases, affiliated with Harvard University and Broad Institute. Their research focuses on Genetics, Drug development, with particular emphasis on Alzheimer's Disease and Psychiatric disorders. With an h-index of 200, Hyman is among the most cited researchers in the neuroscience field[@orcid2026].
Hyman's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and Psychiatric disorders. Their research group has made significant contributions to the fields of Genetics, Drug development, publishing in high-impact journals including leading neuroscience journals.
Based at Harvard University and Broad Institute, Hyman collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- Psychiatric disorders
Mechanisms of Interest
- [Genetics](/mechanisms/familial-alzheimers-genetics)
- Drug development
Programmatic Emphasis
Hyman's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease and Psychiatric disorders[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant[@van2016].
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Genetics, Drug development domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[PubMed author search for Steven M. Hyman](https://pubmed.ncbi.nlm.nih.gov/?term=Steven+M.+Hyman%5BAuthor%5D)[@orcid2026]
[Google Scholar author search for Steven M. Hyman](https://scholar.google.com/scholar?q=author%3A%22Steven+M.+Hyman%22)[@orcid2026]
[Semantic Scholar profile search for Steven M. Hyman](https://www.semanticscholar.org/search?q=Steven+M.+Hyman)[@orcid2026]
Recent Research
Recent PubMed-indexed publications (2025-present):
[Tablet-Based Assessment of Picture Naming in Prodromal Alzheimer's Disease: An Accessible and Effective Tool for Distinguishing Mild Cognitive Impairment from Normal Aging.](https://pubmed.ncbi.nlm.nih.gov/40499520/). Dementia and geriatric cognitive disorders. 2026.
[MICK (Mobile Integrated Cognitive Kit) App for Concussion Assessment in a Youth Ice Hockey League.](https://pubmed.ncbi.nlm.nih.gov/39016256/). Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2025.
[Towards a consensus roadmap for a new diagnostic framework for mental disorders.](https://pubmed.ncbi.nlm.nih.gov/39341044/). European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2025.
Collaborators and Research Network
[John Hardy](/researchers/john-hardy), [Lennart Mucke](/researchers/lennart-mucke)
Institutional Context
Primary institutional links: [Harvard University](/institutions/harvard-university), [Broad Institute](/institutions/broad-institute). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Genetics, Drug development signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Psychiatric disorders into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0003-2605-0010](https://orcid.org/0000-0003-2605-0010)
- Google Scholar: [Search for Steven M. Hyman](https://scholar.google.com/scholar?q=author%3A%22Steven+M.+Hyman%22)
- PubMed: [Author search for Steven M. Hyman](https://pubmed.ncbi.nlm.nih.gov/?term=Steven+M.+Hyman%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
Unknown, ORCID profile for Steven M. Hyman (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)
[Van Cauwenberghe et al, The genetic landscape of Alzheimer disease 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/27916929/)